CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
The HE1 clinical trial has permanently closed, the study confirmed that the quality-of-life benefits of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases. This trial no longer requires action, including the cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals.
Primary Publication
The CCTG CO32 clinical trial testing chemotherapy alone versus chemotherapy plus radiotherapy prior to limited surgery for early rectal cancer has initiate in Canada.
The Canadian Cancer Trials Group (CCTG) is currently seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI) and Chair in Clinical Trials at Queens University.
Dr Branton was a dear friend of CCTG and a pioneer in the study of viral oncogenesis. His work has had far-reaching implications for cancer therapies and remain influential in the development of novel treatments. He played a pivotal role in shaping cancer research in Canada, serving as the inaugural Scientific Director of the Institute of Cancer Research at the Canadian Institutes of Health Research as well as spearheading the formation of the Canadian Cancer Research Alliance.
The Pharmacy Network Steering Committee is actively seeking a Pharmacist Representative for the Lung Disease Site Committee. The Pharmacy Disease Site Committee representative is expected to represent the perspective of the Pharmacist community during discussion of potential new studies and ongoing trials.
Please review terms of reference at: https://www.ctg.queensu.ca/private/pharm_net/pharmacists-network
The Journal of Clinical Oncology has published ‘Correlative Science in the Cooperative Group System—Re-Engineering for Success,’ which proposes public-private partnerships to increase resources and process innovations to open access to tissue banks
The GA1 TOPGEAR trial results were presented at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain and simultaneously published in the
